drugset / Trial / NCT00622414
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of aflibercept in treating young patients with relapsed or refractory solid tumors. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor.
Timeline
- Start
- 2008-04
- Primary completion
- 2010-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | — | Intravenous |